1,623
Views
15
CrossRef citations to date
0
Altmetric
Original Research

Syngeneic Syrian hamster tumors feature tumor-infiltrating lymphocytes allowing adoptive cell therapy enhanced by oncolytic adenovirus in a replication permissive setting

, , , , , , , & show all
Article: e1136046 | Received 22 Oct 2015, Accepted 18 Dec 2015, Published online: 11 May 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Shao-Chia Lu & Michael A Barry. (2022) Locked and loaded: engineering and arming oncolytic adenoviruses to enhance anti-tumor immune responses. Expert Opinion on Biological Therapy 22:11, pages 1359-1378.
Read now
Victor Cervera-Carrascon, Dafne C.A. Quixabeira, Joao Manuel Santos, Riikka Havunen, Sadia Zafar, Otto Hemminki, Camilla Heiniö, Eleonora Munaro, Mikko Siurala, Suvi Sorsa, Tuomas Mirtti, Petrus Järvinen, Markus Mildh, Harry Nisen, Antti Rannikko, Marjukka Anttila, Anna Kanerva & Akseli Hemminki. (2020) Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition. OncoImmunology 9:1.
Read now
Jonathan G. Pol, Sarah Lévesque, Samuel T. Workenhe, Shashi Gujar, Fabrice Le Boeuf, Derek R. Clements, Jean-Eudes Fahrner, Laetitia Fend, John C. Bell, Karen L. Mossman, Jitka Fucikova, Radek Spisek, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2018) Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors. OncoImmunology 7:12.
Read now

Articles from other publishers (12)

Yangyang Jia, Yanru Wang, Louisa S Chard Dunmall, Nicholas R. Lemoine, Pengju Wang & Yaohe Wang. (2023) Syrian hamster as an ideal animal model for evaluation of cancer immunotherapy. Frontiers in Immunology 14.
Crossref
Camilla Heiniö, James Clubb, Tatiana Kudling, Dafne Quixabeira, Victor Cervera-Carrascon, Riikka Havunen, Susanna Grönberg-Vähä-Koskela, João Manuel Santos, Johanna Tapper, Anna Kanerva & Akseli Hemminki. (2022) Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian Cancers. Diseases 10:3, pages 52.
Crossref
Joao Santos, Camilla Heiniö, Dafne Quixabeira, Sadia Zafar, James Clubb, Santeri Pakola, Victor Cervera-Carrascon, Riikka Havunen, Anna Kanerva & Akseli Hemminki. (2021) Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers. Cells 10:5, pages 978.
Crossref
Victor Cervera-Carrascon, Dafne C.A. Quixabeira, Riikka Havunen, Joao M. Santos, Emma Kutvonen, James H.A. Clubb, Mikko Siurala, Camilla Heiniö, Sadia Zafar, Teija Koivula, Dave Lumen, Marjo Vaha, Arturo Garcia-Horsman, Anu J. Airaksinen, Suvi Sorsa, Marjukka Anttila, Veijo Hukkanen, Anna Kanerva & Akseli Hemminki. (2020) Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors. Molecular Therapy - Oncolytics 17, pages 47-60.
Crossref
Mary K. McKenna, Amanda Rosewell-Shaw & Masataka Suzuki. (2020) Modeling the Efficacy of Oncolytic Adenoviruses In Vitro and In Vivo: Current and Future Perspectives. Cancers 12:3, pages 619.
Crossref
Amanda Rosewell Shaw & Masataka Suzuki. (2019) Immunology of Adenoviral Vectors in Cancer Therapy. Molecular Therapy - Methods & Clinical Development 15, pages 418-429.
Crossref
Riikka Havunen, João M. Santos, Suvi Sorsa, Tommi Rantapero, Dave Lumen, Mikko Siurala, Anu J. Airaksinen, Victor Cervera-Carrascon, Siri Tähtinen, Anna Kanerva & Akseli Hemminki. (2018) Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus. Molecular Therapy - Oncolytics 11, pages 109-121.
Crossref
João Manuel Santos, Víctor Cervera-Carrascon, Riikka Havunen, Sadia Zafar, Mikko Siurala, Suvi Sorsa, Marjukka Anttila, Anna Kanerva & Akseli Hemminki. (2018) Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy. Molecular Therapy 26:9, pages 2243-2254.
Crossref
Joao Manuel Santos, Riikka Havunen, Mikko Siurala, Víctor Cervera‐Carrascon, Siri Tähtinen, Suvi Sorsa, Marjukka Anttila, Pauliina Karell, Anna Kanerva & Akseli Hemminki. (2017) Adenoviral production of interleukin‐2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy. International Journal of Cancer 141:7, pages 1458-1468.
Crossref
Riikka Havunen, Mikko Siurala, Suvi Sorsa, Susanna Grönberg-Vähä-Koskela, Michael Behr, Siri Tähtinen, João Manuel Santos, Pauliina Karell, Juuso Rusanen, Dirk M. Nettelbeck, Anja Ehrhardt, Anna Kanerva & Akseli Hemminki. (2017) Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy. Molecular Therapy - Oncolytics 4, pages 77-86.
Crossref
Siri Tähtinen, Carolin Blattner, Markus Vähä-Koskela, Dipongkor Saha, Mikko Siurala, Suvi Parviainen, Jochen Utikal, Anna Kanerva, Viktor Umansky & Akseli Hemminki. (2016) T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFα Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma. Journal of Immunotherapy 39:9, pages 343-354.
Crossref
Mikko Siurala, Riikka Havunen, Dipongkor Saha, Dave Lumen, Anu J. Airaksinen, Siri Tähtinen, Víctor Cervera-Carrascon, Simona Bramante, Suvi Parviainen, Markus Vähä-Koskela, Anna Kanerva & Akseli Hemminki. (2016) Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma. Molecular Therapy 24:8, pages 1435-1443.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.